Androgens and androgen receptors in breast cancer

Journal of Steroid Biochemistry and Molecular Biology

Volumn 105, Issue 1-5, 2007, Pages 1-15

  Nicolas Diaz Chico B ^a,b   German Rodriguez F ^a,b   González, Ana ^a,c   Ramírez, Raquel ^a   Bilbao, Cristina ^a   Cabrera de Leon A ^a,c   Aguirre Jaime, A ^a,c   Chirino, Ricardo ^a,b   Navarro, Domingo ^a,b   Díaz Chico, Juan C ^a,b  

^a Madrid Spain   (Spain)

^b UNIVERSITY OF LAS PALMAS DE GRAN CANARIA   (Spain)

^c HOSPITAL UNIVERSITARIO NUESTRA SEÑORA DE CANDELARIA   (Spain)

Author keywords

Androgen; Androgen receptor; Breast cancer; Carcinogenesis; Gene polymorphism

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; ANDROSTENEDIONE; AROMATASE; ESTROGEN; ESTROGEN RECEPTOR; POLYGLUTAMINE; PRASTERONE; PRASTERONE SULFATE; TESTOSTERONE;

BREAST CANCER; BREAST CARCINOGENESIS; CANCER GROWTH; CANCER RISK; GENETIC POLYMORPHISM; HORMONE RECEPTOR INTERACTION; HUMAN; PROGNOSIS; REVIEW; TESTOSTERONE BLOOD LEVEL;

ANDROGENS; BREAST NEOPLASMS; DISEASE PROGRESSION; HUMANS; POLYMORPHISM, GENETIC; RECEPTORS, ANDROGEN; RISK ASSESSMENT;

EID: 34547670428     PISSN: 09600760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jsbmb.2006.11.019     Document Type: Review

References (115)

1. Honma N., Takubo K., Sawabe M., Arai T., Akiyama F., Sakamoto G., Utsumi T., Yoshimura N., and Harada N. Estrogen-metabolizing enzymes in breast cancers from women over the age of 80 years. J. Clin. Endocrinol. Metab. 91 2 (2006) 607-613
2. Pasqualini J.R., and Chetrite G.S. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J. Steroid Biochem. Mol. Biol. 93 2-5 (2005) 221-236 (Review)
3. Sasano H., Suzuki T., Nakata T., and Moriya T. New development in intracrinology of breast carcinoma. Breast Cancer 13 2 (2006) 129-136 (Review)
4. Yager J.D., and Davidson N.E. Estrogen carcinogenesis in breast cancer. N. Engl. J. Med. 354 3 (2006) 270-282 (Review)
5. Clemons M., and Goss P. Estrogen and the risk of breast cancer. N. Engl. J. Med. 344 4 (2001) 276-285 (Review)
6. Kurebayashi J. Endocrine-resistant breast cancer: underlying mechanisms and strategies for overcoming resistance. Breast Cancer 10 2 (2003) 112-119 (Review)
7. Shang Y. Molecular mechanisms of oestrogen and SERMs in endometrial carcinogenesis. Nat. Rev. Cancer 6 5 (2006) 360-368 (Review)
8. Kaaks R., Rinaldi S., Key T.J., Berrino F., Peeters P.H., Biessy C., Dossus L., Lukanova A., Bingham S., Khaw K.T., Allen N.E., Bueno-de-Mesquita H.B., van Gils C.H., Grobbee D., Boeing H., Lahmann P.H., Nagel G., Chang-Claude J., Clavel-Chapelon F., Fournier A., Thiebaut A., González C.A., Quiros J.R., Tormo M.J., Ardanaz E., Amiano P., Krogh V., Palli D., Panico S., Tumino R., Vineis P., Trichopoulou A., Kalapothaki V., Trichopoulos D., Ferrari P., Norat T., Saracci R., and Riboli E. Postmenopausal serum androgens, oestrogens and breast cancer risk: the European prospective investigation into cancer and nutrition. Endocr. Relat. Cancer 12 4 (2005) 1071-1082
9. Wang D.Y., Allen D.S., De Stavola B.L., Fentiman I.S., Brussen J., and Bulbrook R.D. Urinary androgens and breast cancer risk: results from a long-term prospective study based in Guernsey. Br. J. Cancer 82 (2000) 1577-1584
10. Zeleniuch-Jacquotte A., Gu Y., Shore R.E., Koenig K.L., Arslan A.A., Kato I., Rinaldi S., Kaaks R., and Toniolo P. Postmenopausal levels of sex hormones and risk of breast carcinoma in situ: results of a prospective study. Int. J. Cancer 114 2 (2005) 323-327
11. Yu H., Shu X.O., Shi R., Dai Q., Jin F., Gao Y.T., Li B.D., and Zheng W. Plasma sex steroid hormones and breast cancer risk in Chinese women. Int. J. Cancer 105 1 (2003) 92-97
12. Dorgan J.F., Longcope C., Stephenson Jr. H.E., Falk R.T., Miller R., Franz C., Kahle L., Campbell W.S., Tangrea J.A., and Schatzkin A. Serum sex hormone levels are related to breast cancer risk in postmenopausal women. Environ. Health Perspect. 105 3 (1997) 583-585
13. Hankinson S.E., Willett W.C., Manson J.E., Colditz G.A., Hunter D.J., Spiegelman D., Barbieri R.L., and Speizer F.E. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J. Natl. Cancer Inst. 90 17 (1998) 1292-1299
14. Cauley J.A., Lucas F.L., Kuller L.H., Stone K., Browner W., and Cummings S.R. Elevated serum estradiol and testosterone concentrations are associated with a high risk for breast cancer, study of osteoporotic fractures research group. Ann. Intern. Med. 130 4 (1999) 270-277
15. Missmer S.A., Eliassen A.H., Barbieri R.L., and Hankinson S.E. Endogenous estrogen, androgen, and progesterone concentrations and breast cancer risk among postmenopausal women. J. Natl. Cancer Inst. 96 24 (2004) 1856-1865
16. Schairer C., Hill D., Sturgeon S.R., Fears T., Mies C., Ziegler R.G., Hoover R.N., and Sherman M.E. Serum concentrations of estrogens, sex hormone binding globulin, and androgens and risk of breast hyperplasia in postmenopausal women. Cancer Epidemiol Biomarkers Prev. 14 7 (2005) 1660-1665
17. Grattarola R. The premenstrual endometrial pattern of women with breast cancer. A study of progestional activity. Cancer 17 (1964) 1119-1122
18. Grattarola R. Androgens in breast cancer. Atypical endometrial hyperplasia and breast cancer in married premenopausal women. Am. J. Obstet. Gynecol. 116 (1973) 423-428
19. Secreto G., Toniolo P., Pisani P., Recchione C., Cavalleri A., and Fariselli G. Androgens and breast cancer in premenopausal women. Cancer Res. 49 (1989) 471-476
20. Somboonporn W., and Davis S.R. Testosterone effects on the breast: implications for testosterone therapy for women. Endocr. Rev. 25 3 (2004) 374-388
21. The Endogenous Hormones and Breast Cancer Collaborative Group. Endogenous steroid hormones and breast cancer risk in postmenopausal women: analysis of nine prospective studies. J. Natl. Cancer Inst. 94 (2002) 606-616
22. Secreto G., and Zumoff B. Abnormal production of androgens in women with breast cancer. Anticancer Res. 14 (1994) 2113-2117
23. Page J.H., Colditz G.A., Rifai N., Barbieri R.L., Willett W.C., and Hankinson S.E. Plasma adrenal androgens and risk of breast cancer in premenopausal women. Cancer Epidemiol. Biomarkers Prev. 13 (2004) 1032-1036
24. Recchione C., Venturelli E., Manzari A., Cavalleri A., Martinetti A., and Secreto G. Testosterone, dihydrotestosterone and oestradiol levels in postmenopausal breast cancer tisúes. J. Steroid Biochem. Mol. Biol. 52 6 (1995) 541-546
25. Secreto G., Venturelli E., Bucci A., Piromalli D., Fariselli G., and Galante E. Intratumour amount of sex steroids in elderly breast cancer patients, An approach to the biological characterization of mammary tumours in the elderly. J. Steroid Biochem. Mol. Biol. 58 5-6 (1996) 557-561
26. Secreto G., Recchione C., Ballerini P., Callegari L., Cavalleri A., Attili A., Fariselli G., Moglia D., and Del Prato I. Accumulation of active androgens in breast cyst fluids. Eur. J. Cancer 27 1 (1991) 44-47
27. Feldman B.J., and Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer 1 1 (2001) 34-45 (Review)
28. Kaaks R., Berrino F., Key T., Rinaldi S., Dossus L., Biessy C., Secreto G., Amiano P., Bingham S., Boeing H., Bueno de Mesquita H.B., Chang-Claude J., Clavel-Chapelon F., Fournier A., van Gils C.H., González C.A., Gurrea A.B., Critselis E., Khaw K.T., Krogh V., Lahmann P.H., Nagel G., Olsen A., Onland-Moret N.C., Overvad K., Palli D., Panico S., Peeters P., Quiros J.R., Roddam A., Thiebaut A., Tjonneland A., Chirlaque M.D., Trichopoulou A., Trichopoulos D., Tumino R., Vineis P., Norat T., Ferrari P., Slimani N., and Riboli E. Serum sex steroids in premenopausal women and breast cancer risk within the European Prospective Investigation into Cancer and Nutrition (EPIC). J. Natl. Cancer Inst. 97 10 (2005) 755-765
29. Dimitrakakis C., Zhou J., and Bondy C.A. Androgens and mammary growth and neoplasia. Fertil. Steril. 77 Suppl. 4 (2002) S26-S33
30. Pasqualini J.R., and Chetrite G.S. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer. J. Steroid Biochem. Mol. Biol. 93 2-5 (2005) 221-236
31. Xie B., Tsao S.W., and Wong Y.C. Sex hormone-induced mammary carcinogenesis in female noble rats: the role of androgen. Carcinogenesis 20 (1999) 1597-1606
32. Xie B., Tsao S.W., and Wong Y.C. Induction of high incidence of mammary tumour in female Noble rats with a combination of 17-oestradiol and testosterone. Carcinogenesis 20 (1999) 1069-1078
33. Pike M.C., Spicer D.V., Dahmoush L., and Press M.F. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 15 (1993) 17-35
34. Schairer C., Lubin J., Troisi R., Sturgeon S., Brinton L., and Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. JAMA 283 (2000) 485-491
35. Lanari C., and Molinolo A.A. Progesterone receptors-animal models and cell signalling in breast cancer, diverse activation pathways for the progesterone receptor: possible implications for breast biology and cancer. Breast Cancer Res. 4 (2002) 240-243
36. Conneely O.M., Jericevic B.M., and Lydon J.P. Progesterone receptors in mam mary gland development and tumorigenesis. J. Mammary Gland Biol. Neoplasia 8 (2003) 205-214
37. Shi Y.E., Liu Y.E., Lippman M.E., and Dickson R.B. Progestins and antiprogestins in mammary tumour growth and metastasis. Hum. Reprod. 9 Suppl. (1994)
38. Doisneau-Sixou S.F., Sergio C.M., Carroll J.S., Hui R., Musgrove E.A., and Sutherland R.L. Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells. Endocr. Relat. Cancer 10 (2003) 179-186
39. Dickson R.B., and Stancel G.M. Estrogen receptor-mediated processes in normal and cancer cells. J. Natl. Cancer Inst. Monogr. (2000) 135
40. Labrie F., Luu-The V., Labrie C., Belanger A., Simard J., and Lin S.X. Endocrine and intracrine sources of androgens in women: inhibition of breast cancer and other roles of androgens and their precursor dehydroepiandrosterone. Endocr. Rev. 24 (2003) 152-182
41. Baniahmad A. Nuclear hormone receptor co-repressors. J. Steroid Biochem. Mol. Biol. 93 2-5 (2005) 89-97
42. Kang Z., Pirskanen A., Janne O.A., and Palvimo J.J. Involvement of proteasome in the dynamic assembly of the androgen receptor transcription complex. J. Biol. Chem. 277 (2002) 48366-48371
43. Lin H.K., Altuwaijri S., Lin W.J., Kan P.Y., Collins L.L., and Chang C. Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J. Biol. Chem. 277 (2002) 36570-36576
44. Molinari E., Gilman M., and Natesan S. Proteasome-mediated degradation of transcriptional activators correlates with activation domain potency in vivo. EMBO J. 18 (1999) 6439-6447
45. Salghetti S.E., Caudy A.A., Chenoweth J.G., and Tansey W.P. Regulation of transcriptional activation domain function by ubiquitin. Science 293 (2001) 1651-1653
46. Salghetti S.E., Muratani M., Wijnen H., Futcher B., and Tansey W.P. Functional overlap of sequences that activate transcription and signal ubiquitin-mediated proteolysis. Proc. Natl. Acad. Sci. U. S. A. 97 (2000) 3118-3123
47. Lorenzo G.D., Bianco R., Tortora G., and Ciardiello F. Involvement of growth factor receptors of the epidermal growth factor receptor family in prostate cancer development and progression to androgen independence. Clin. Prostate Cancer 2 1 (2003) 50-57
48. Culig Z., Comuzzi B., Steiner H., Bartsch G., and Hobisch A. Expression and function of androgen receptor coactivators in prostate cancer. J. Steroid Biochem. Mol. Biol. 92 4 (2004) 265-271
49. Culig Z. Androgen receptor cross-talk with cell signalling pathways. Growth Factors 22 3 (2004) 179-184 (Review)
50. Sengupta S., and Wasylyk B. Physiological and pathological consequences of the interactions of the p53 tumor suppressor with the glucocorticoid, androgen, and estrogen receptors. Ann. N. Y. Acad. Sci. 1024 (2004) 54-71
51. Allegra J.C., Lippman M.E., Thompson E.B., Simon R., Barlock A., Green L., Huff K.K., Do H.M., and Aitken S.C. Distribution, frequency, and quantitative analysis of estrogen, progesterone, androgen, and glucocorticoid receptors in human breast cancer. Cancer Res. 39 (1979) 1447-1454
52. Hall R.E., Clements J.A., Birrell S.N., and Tilley W.D. Prostate-specific antigen and gross cystic disease fluid protein-15 are co-expressed in androgen receptor-positive breast tumours. Br. J. Cancer 78 (1998) 360-365
53. Kuenen-Boumeester V., Van der Kwast T.H., van Putten W.L., Claassen C., van Ooijen B., and Henzen-Logmans S.C. Immunohistochemical determination of androgen receptors in relation to oestrogen and progesterone receptors in female breast cancer. Int. J. Cancer 52 (1992) 581-584
54. Agoff S.N., Swanson P.E., Linden H., Hawes S.E., and Lawton T.J. Androgen receptor expression in estrogen receptor-negative breast cancer, Immunohistochemical, clinical, and prognostic associations. Am. J. Clin. Pathol. 120 (2003) 725-731
55. Secreto G., Toniolo P., Berrino F., Recchione C., Di Pietro S., and Fariselli G. Increased androgenic activity and breast cancer risk in premenopausal women. Cancer Res. 44 (1984) 5902-5905
56. Isola J.J. Immunohistochemical demonstration of androgen receptor in breast cancer and its relationship to other prognostic factors. J. Pathol. 170 (1993) 31-35
57. Brys M., Wojcik M., Romanowicz-Makowska H., and Krajewska W.M. Androgen receptor status in female breast cancer: RT-PCR and Western blot studies. J. Cancer Res. Clin. Oncol. 128 (2002) 85-90
58. Bieche I., Parfait B., Tozlu S., Lidereau R., and Vidaud M. Quantitation of androgen receptor gene expression in sporadic breast tumors by real-time RT-PCR: evidence that MYC is an AR-regulated gene. Carcinogenesis 22 (2001) 1521-1526
59. Soreide J.A., Lea O.A., Varhaug J.E., Skarstein A., and Kvinnsland S. Androgen receptors in operable breast cancer: relation to other steroid hormone receptors, correlations to prognostic factors and predictive value for effect of adjuvant tamoxifen treatment. Eur. J. Surg. Oncol. 18 (1992) 112-118
60. Shen H.C., and Coetzee G.A. The androgen receptor: unlocking the secrets of its unique transactivation domain. Vitam. Horm. 71 (2005) 301-319
61. Navarro D., Luzardo O.P., Fernandez L., Chesa N., and Diaz-Chico B.N. Transition to androgen-independence in prostate cancer. J. Steroid Biochem. Mol. Biol. 81 3 (2002) 191-201
62. Ding D., Xu L., Menon M., Reddy G.P., and Barrack E.R. Effect of GGC (glycine) repeat length polymorphism in the human androgen receptor on androgen action. Prostate 62 2 (2005) 133-139
63. Hsing A.W., Gao Y.T., Wu G., Wang X., Deng J., Chen Y.L., Sesterhenn I.A., Mostofi F.K., Benichou J., and Chang C. Polymorphic CAG and GGN repeat lengths in the androgen receptor gene and prostate cancer risk: a population-based case-control study in China. Cancer Res. 60 18 (2000) 5111-5116
64. Aschim E.L., Nordenskjold A., Giwercman A., Lundin K.B., Ruhayel Y., Haugen T.B., Grotmol T., and Giwercman Y.L. Linkage between cryptorchidism, hypospadias, and GGN repeat length in the androgen receptor gene. J. Clin. Endocrinol. Metab. 89 10 (2004) 5105-5109
65. Iwakura M., and Nakamura T. Effects of the length of a glycine linker terminal interaction. J. Biol. Chem. 277 (2002) 25631-25639
66. Ding D., Xu L., Menon M., Reddy G.P., and Barrack E.R. Effect of a short CAG (glutamine) repeat on human androgen receptor function. Prostate 58 1 (2004) 23-32
67. Esteban E., Rodon N., Via M., González-Perez E., Santamaria J., Dugoujon J.M., Chennawi F.E., Melhaoui M., Cherkaoui M., Vona G., Harich N., and Moral P. Androgen receptor CAG and GGC polymorphisms in Mediterraneans: repeat dynamics and population relationships. J. Hum. Genet. 51 2 (2006) 129-136
68. Gilbert S.M., Benson M.C., and McKiernan J.M. Linkage disequilibrium between the androgen receptor gene CAG and GGC repeats in the African-American population. Curr. Urol. Rep. 3 3 (2002) 189-193 (Review)
69. Rodriguez G., Bilbao C., Ramirez R., Falcon O., Leon L., Chirino R., Falcon Jr. O., Diaz B.P., Rivero J.F., Perucho M., Diaz-Chico B.N., and Diaz-Chico J.C. Alleles with short CAG and GGN repeats in the androgen receptor gene are associated with benign endometrial cancer. Int. J. Cancer 118 (2006) 1420-1425
70. Zeegers M.P., Kiemeney L.A., Nieder A.M., and Ostrer H.R. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk?. Cancer Epidemiol. Biomarkers Prev. 13 11 (2004) 1765-1771
71. Beitel L.K., Scanlon T., Gottlieb B., and Trifiro M.A. Progress in Spinobulbar muscular atrophy research: insights into neuronal dysfunction caused by the polyglutamine-expanded androgen receptor. Neurotox Res. 7 3 (2005) 219-230
72. Poletti A. The polyglutamine tract of androgen receptor: from functions to dysfunctions in motor neurons. Front Neuroendocrinol. 25 1 (2004) 1-26 (Review)
73. Piccioni F., Simeoni S., Andriola I., Armatura E., Bassanini S., Pozzi P., and Poletti A. Polyglutamine tract expansion of the androgen receptor in a motoneuronal model of spinal and bulbar muscular atrophy. Brain Res. Bull. 1 56 (2001) 215-220 (Review)
74. La Spada A.R., Wilson E.M., Lubahn D.B., Harding A.E., and Fischbeck K.H. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy. Nature 4 352 (1991) 77-79
75. Walcott J.L., and Merry D.E. Trinucleotide repeat disease, the androgen receptor in spinal and bulbar muscular atrophy. Vitam. Horm. 65 (2002) 127-147 (Review)
76. Hakimi J.M., Schoenberg M.P., Rondinelli R.H., Piantadosi S., and Barrack E.R. Androgen receptor variants with short glutamine or glycine repeats may identify unique subpopulations of men with prostate cancer. Clin. Cancer Res. 3 (1997) 1599-1608
77. Chamberlain N.L., Driver E.D., and Miesfeld R.L. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucl. Acids Res. 22 (1994) 3181-3186
78. Rebbeck T.R., Kantoff P.W., Krithivas K., Neuhausen S., Blackwood M.A., Godwin A.K., Daly M.B., Narod S.A., Garber J.E., Lynch H.T., Weber B.L., and Brown M. Modification of BRCA1-associated breast cancer risk by the polymorphic androgen-receptor CAG repeat. Am. J. Hum. Genet. 64 (1999) 1371-1377
79. Clark P.E., Irvine R.A., and Coetzee G.A. The androgen receptor CAG repeat and prostate cancer risk. Methods Mol. Med. 81 (2003) 255-266 (Review)
80. Zeegers M.P., Kiemeney L.A., Nieder A.M., and Ostrer H.R. How strong is the association between CAG and GGN repeat length polymorphisms in the androgen receptor gene and prostate cancer risk?. Cancer Epidemiol. Biomarkers Prev. 13 (2004) 1765-1771
81. Beilin J., Ball E.M., Favaloro J.M., and Zajac J.D. Effect of the androgen receptor CAG repeat polymorphism on transcriptional activity: specificity in prostate and non-prostate cell lines. J. Mol. Endocrinol. 25 (2000) 85-96
82. Ferro P., Catalano M.G., Dell'Eva R., Fortunati N., and Pfeffer U. The androgen receptor CAG repeat: a modifier of carcinogenesis?. Mol. Cell Endocrinol. 31 193 (2002) 109-120 (Review)
83. Lieberman A.P., Harmison G., Strand A.D., Olson J.M., and Fischbeck K.H. Altered transcriptional regulation in cells expressing the expanded polyglutamine androgen receptor. Hum. Mol. Genet. 11 (2002) 1967-1976
84. Stenoien D.L., Cummings C.J., Adams H.P., Mancini M.G., Patel K., DeMartino G.N., Marcelli M., Weigel N.L., and Mancini M.A. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum. Mol. Genet. 8 (1999) 731-741
85. Nawaz Z., and O'Malley B.W. Urban renewal in the nucleus: is protein turnover by proteasomes absolutely required for nuclear receptor-regulated transcription?. Mol. Endocrinol. 18 (2004) 493-499
86. Westberg L., Baghaei F., Rosmond R., Hellstrand M., Landen M., Jansson M., Holm G., Bjorntorp P., and Eriksson E. Polymorphisms of the androgen receptor gene and the estrogen receptor beta gene are associated with androgen levels in women. J. Clin. Endocrinol. Metab. 86 (2001) 2562-2568
87. Ibañez L., Ong K.K., Mongan N., Jaaskelainen J., Marcos M.V., Hughes I.A., De Zegher F., and Dunger D.B. Androgen receptor gene CAG repeat polymorphism in the Development of ovarian hyperandrogenism. J. Clin. Endocrinol. Metab. 88 (2003) 3333-3338
88. Brum I.S., Spritzer P.M., Paris F., Maturana M.A., Audran F., and Sultan C. Association between androgen receptor gene CAG repeat polymorphism and plasma testosterone levels in postmenopausal women. J. Soc. Gynecol. Investig. 12 (2005) 135-141
89. Hietala M., Sandberg T., Borg A., Olsson H., and Jernström H. Testosterone levels in relation to oral contraceptive use and the androgen receptor CAG and GGC length polymorphisms in healthy young women. Hum. Reprod. (2006) (Advance Access, August 18)
90. Zava D.T., and McGuire W.L. Estrogen receptors in androgen-induced breast tumor regression. Cancer Res. 37 (1977) 1608-1610
91. Horwitz K.B., Costlow M.E., and McGuire W.L. MCF-7; a human breast cancer cell line with estrogen, androgen, progesterone, and glucocorticoid receptors. Steroids 26 (1975) 785-795
92. Wooster R., Mangion J., Eeles R., Smith S., Dowsett M., Averill D., Barrett-Lee P., Easton D.F., Ponder B.A., and Stratton M.R. A germline mutation in the androgen receptor gene in two brothers with breast cancer and Reifenstein syndrome. Nat. Genet. 2 (1992) 132-134
93. MacLean H.E., Brown R.W., Beilin J., Warne G.L., and Zajac J.D. Increased frequency of long androgen receptor CAG repeats in male breast cancers. Breast Cancer Res. Treat. 88 3 (2004) 239-246
94. Giguiere Y., Dewailly E., Brisson J., Ayotte P., Laflamme N., Demers A., Forest V.I., Dodin S., Robert J., and Rousseau F. Short polyglutamine tracts in the androgen receptor are protective against breast cancer in the general population. Cancer Res. 61 (2001) 5869-5874
95. Liede A., Zhang W., De Leon Matsuda M.L., Tan A., and Narod S.A. Androgen receptor gene polymorphism and breast cancer susceptibility in The Philippines. Cancer Epidemiol. Biomarkers Prev. 12 9 (2003) 848-852
96. Brum I.S., Spritzer P.M., Paris F., Maturana M.A., Audran F., and Sultan C. Association between androgen receptor gene CAG repeat polymorphism and plasma testosterone levels in postmenopausal women. J. Soc. Gynecol. Investig. 12 2 (2005) 135-141
97. Dagan E., Friedman E., Paperna T., Carmi N., and Gershoni-Baruch R. Androgen receptor CAG repeat length in Jewish Israeli women who are BRCA1/2 mutation carriers: association with breast/ovarian cancer phenotype. Eur. J. Hum. Genet. 10 11 (2002) 724-728
98. EMBRACE Study Collaborators. The androgen receptor CAG repeat polymorphism and modification of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Breast Cancer Res. 7 2 (2005) 176-183
99. Kadouri L., Easton D.F., Edwards S., Hubert A., Kote-Jarai Z., Glaser B., Durocher F., Abeliovich D., Peretz T., and Eeles R.A. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers. Br. J. Cancer 85 (2001) 36-40
100. Dunning A.M., McBride S., Gregory J., Durocher F., Foster N.A., Healey C.S., Smith N., Pharoah P.D., Luben R.N., Easton D.F., and Ponder B.A. No association between androgen or vitamin D receptor gene polymorphisms and risk of breast cancer. Carcinogenesis 20 (1999) 2131-2135
101. Menin C., Banna G.L., De Salvo G., Lazzarotto V., De Nicolo A., Agata S., Montagna M., Sordi G., Nicoletto O., Chieco-Bianchi L., and D'Andrea E. Lack of association between androgen receptor CAG polymorphism and familial breast/ovarian cancer. Cancer Lett. 168 (2001) 31-36
102. Elhaji Y.A., Gottlieb B., Lumbroso R., Beitel L.K., Foulkes W.D., Pinsky L., and Trifiro M.A. The polymorphic CAG repeat of the androgen receptor gene: a potential role in breast cancer in women over 40. Breast Cancer Res. Treat. 70 (2001) 109-116
103. Wang W., John E.M., and Ingles S.A. Androgen receptor and prostate-specific antigen gene polymorphisms and breast cancer in African-American women. Cancer Epidemiol. Biomarkers Prev. 14 12 (2005) 2990-2994
104. Iobagiu C., Lambert C., Normand M., and Genin C. Microsatellite profile in hormonal receptor genes associated with breast cancer. Breast Cancer Res. Treat. 95 2 (2006) 153-159
105. Spurdle A.B., Dite G.S., Chen X., Mayne C.J., Southey M.C., Batten L.E., Chy H., Trute L., McCredie M.R., Giles G.G., Armes J., Venter D.J., Hopper J.L., and Chenevix-Trench G. Androgen receptor exon 1 CAG repeat length and breast cancer in women before age forty years. J. Natl. Cancer Inst. 91 11 (1999) 961-966
106. Haiman C.A., Brown M., Hankinson S.E., Spiegelman D., Colditz G.A., Willett W.C., Kantoff P.W., and Hunter D.J. The androgen receptor CAG repeat polymorphism and risk of breast cancer in the Nurses' Health Study. Cancer Res. 62 (2002) 1045-1049
107. A. González, F.J. Dorta, F.G. Rodríguez, B. Brito, M.C. Rodríguez, A.Cabrera, J.C. Díaz-Chico, R. Reyes, A. Aguirre-Jaime, B.N. Díaz-Chico, Increased Risk of Breast Cancer in Women Bearing a Combination of Large CAG and GGN Repeats in the Exon 1 of the Androgen Receptor Gene, Eur. J. Cancer (2007), in press.
108. n polymorphism and breast cancer risk in a population-based case-control study of young women. Cancer Epidemiol. Biomarkers Prev. 12 (2003) 127-135
109. Ursin G., Ma H., Wu A.H., Bernstein L., Salane M., Parisky Y.R., Astrahan M., Siozon C.C., and Pike M.C. Mammographic density and breast cancer in three ethnic groups. Cancer Epidemiol. Biomarkers Prev. 12 4 (2003) 332-338
110. Yu H., Bharaj B., Vassilikos E.J., Giai M., and Diamandis E.P. Shorter CAG repeat length in the androgen receptor gene is associated with more aggressive forms of breast cancer. Breast Cancer Res. Treat. 59 (2000) 153-161
111. Betancor E., Rodriguez G., González A., Cabrera A., Sanchez M., Vega V., Murias A., Bohn U., Limeres M., Pestano J., Diaz-Chico B.N., and Diaz-Chico J.C. The androgen receptor gene polymorphisms in human breast cancer: Short CAG repeats are associated with lymph node involvement. 28th Annual San Antonio Breast Cancer Symposium. San Antonio, Texas, USA (2005)
112. Slattery M.L., Sweeney C., Murtaugh M., Ma K.N., Caan B.J., Potter J.D., and Wolff R. Associations between vitamin D, vitamin D receptor gene and the androgen receptor gene with colon and rectal cancer. Int. J. Cancer 118 12 (2006) 3140-3146
113. Slattery M.L., Sweeney C., Murtaugh M., Ma K.N., Wolff R.K., Potter J.D., Caan B.J., and Samowitz W. Associations between ERalpha, ERbeta, and AR genotypes and colon and rectal cancer. Cancer Epidemiol. Biomarkers Prev. 14 12 (2005) 2936-2942
114. Platz E.A., Giovannucci E., Dahl D.M., Krithivas K., Hennekens C.H., Brown M., Stampfer M.J., and Kantoff P.W. The androgen receptor gene GGN microsatellite and prostate cancer risk. Cancer Epidemiol. Biomarkers Prev. 7 (1998) 379-384
115. Dietzsch E., Laubscher R., and Parker M.I. Esophageal cancer risk in relation to GGC and CAG trinucleotide repeat lengths in the androgen receptor gene. Int. J. Cancer 20 107 (2003) 38-45